<div id="readability-page-1"><div><p>BOCI issued a report stating that PHARMARON (03759.HK)<span> </span><span> -0.640 (-2.947%)  </span> <span> Short selling $5.57M; Ratio 5.772%  </span>  recorded revenue of RMB3.58 billion in 1Q26, up 15.5% YoY, while adjusted net profit increased 16.2% YoY. Newly signed orders rose by more than 30% YoY, of which laboratory services grew by over 20% and small-molecule CDMO expanded by more than 50%. Management maintained its full-year revenue growth target of 1218%.</p><p>BOCI raised its revenue forecasts for PHARMARON for 20262027 by 3.6% and 6.5%, respectively, reflecting faster project conversion driven by accelerating new orders and robust demand for small-molecule CDMO services. Adjusted profit is expected to remain broadly stable in the near term. The broker slightly lifted its TP from HKD25 to HKD26, implying 20x 2026 PE, broadly in line with WuXi AppTec. Compared with high-growth CDMO peers such as Asymchem, the company still trades at a discount, mainly due to its relatively weaker positioning in new molecule deployment. Considering that the company is in a phase of rising CDMO contribution and improving profitability, BOCI maintained its Buy rating. (ha/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-30 12:25.)</p></div><p>This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.</p></div>

300759

159892

513060

<p>BOCI has raised its target price for PHARMARONfrom HKD25 to HKD26, maintaining a Buy rating. The company reported a 15.5% YoY revenue increase to RMB3.58 billion in 1Q26, with adjusted net profit up 16.2% YoY. Newly signed orders rose over 30% YoY, driven by strong demand for laboratory services and small-molecule CDMO. BOCI also increased its revenue forecasts for 2026 and 2027 by 3.6% and 6.5%, respectively, citing faster project conversion. Despite trading at a discount compared to peers, PHARMARON's profitability is improving as CDMO contributions rise.</p>

AASTOCKS News

Pharmaron

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

PHARMARON

WuXi AppTec

WUXI APPTEC

Asymchem

BOCI Raises PHARMARON  TP to HKD26, Maintains Buy